ClinicalTrials.gg
CompletedNCT01844765DIALOGUpdated Apr 22, 2021Results posted

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

A Phase 2 interventional study of nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 13 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
31st of 66
59 · median 55
Started
2013
with 10 others
Phase 2
25 of 66
1 open now
Registered
44th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 31st largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 44th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to \<18 years).

Read the detailed description

The study was designed as a multi-center, open-label, non-controlled phase II study to assess efficacy, safety and PK parameters of 230 mg/m2 twice daily nilotinib in pediatric patients (1 to \<18 years old). The study population consisted of three cohorts of Ph+ CML pediatric patients:

  • Cohort 1: Ph+ CML-CP patients resistant or intolerant to either imatinib or dasatinib
  • Cohort 2: Ph+ CML-AP patients resistant or intolerant to either imatinib or dasatinib
  • Cohort 3: Newly-diagnosed Ph+ CML-CP patients in first chronic phase A minimum number of 50 pediatric patients (from 1 to \<18 years) were enrolled in the study. Of them, at least 15 patients were Ph+ CML-CP patients resistant or intolerant to either imatinib or dasatinib, and at least 15 were newly-diagnosed Ph+ CML-CP patients in first chronic phase patients. There was no minimum number of patients required for Ph+ CML-AP patients resistant or intolerant to either imatinib or dasatinib.

Based on enrollment forecasts as of Jan 2015, and to reflect the agreements with the US FDA and the PDCO, the study remained open for enrollment until the targeted number of 50 patients with at least 15 newly diagnosed Ph+CML patients was achieved or until 31May2015, whichever was later.

Patients who completed the study were treated with nilotinib for a total of 66 cycles of 28 days unless the patient prematurely discontinued study treatment.

The primary analysis cut-off date was the date when all patients enrolled in the trial either completed their visit for treatment cycle 12 or had discontinued study treatment early (EoT/early discontinuation visit). These analyses were reported in the 12-cycle clinical study report (CSR). A 24-cycle analysis was done when all patients had either completed their 24-cycle treatment visit or had discontinued study treatment early.

At trial end, a final comprehensive CSR of all data collected during the trial was produced.

03

Conditions studied

  • Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

Keywords

  • Tasigna
  • nilotinib treatment
  • chronic phase
  • Ph+ CML
  • accelerated phase
  • newly diagnosed Ph+ CML
  • pediatric
  • leukemia
  • leukemia, pediatric
  • leukemia, myleiod
  • leukemia, mylegenous, chronic
  • leukemia, mylegenous, accelerated
  • BCR-ABL positive
  • myeloproliferative disorder
  • bone marrow disease
  • hematologic diseases
  • neoplastic processes
  • imatinib
  • dasatinib
  • enzyme inhibitor
  • protein kinase inhibitor
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib
  • ≥ 50% for patients > 10 years of age and Lansky ≥ 50 for patients ≤ 10 years of age
  • Adequate renal, hepatic and pancreatic function
  • Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal)
  • Written

Key Exclusion Criteria:

  • Treatment with strong inhibitors or inducers
  • Use or planned use of any medications that have a known risk or possible risk to prolong the
  • Acute or chronic liver, pancreatic or severe renal disease
  • History of pancreatitis or chronic pancreatitis.
  • Impaired cardiac function
  • No evidence of active graft vs host and \<3mo since Stem Cell Transplant
  • Total body irradiation (TBI) or craniospinal radiation therapy \<6months
  • to the active ingredient or any of the including lactose.
  • the criteria regarding pregnancy and
  • Active or systemic bacterial, fungal, or viral infection
  • known , , or infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Newly diagnosed and untreated Ph+ CML in first CP

    Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.

    Drug: nilotinib

  • Experimental
    Resistant/intolerant Ph+ CML in CP

    Resistant or Intolerant to either imatinib or dasatinib

    Drug: nilotinib

  • Experimental
    Resistant/intolerant Ph+ CML in AP

    Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.

    Drug: nilotinib

Interventions

  • Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib

    MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.

    Time frame: 6 cycles

  2. MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients

    MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.

    Time frame: 12 cycles

  3. Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients

    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.

    Time frame: 12 cycles

Secondary outcomes

  1. MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib

    Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

    Time frame: By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days)

  2. MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients

    Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

    Time frame: by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days)

  3. Best BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall

    MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)

    Time frame: up to 66 cycles (1 cycle = 28 days)

  4. Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall

    MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)

    Time frame: up to 66 cycles (1 cycle = 28 days)

  5. Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR

    Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.

    Time frame: From first dosing to the first MMR within 66 cycles period

  6. Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR

    Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.

    Time frame: From first dosing to the first MMR within 66 cycles period

  7. Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR

    Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.

    Time frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles)

  8. Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR

    Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.

    Time frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles)es)

  9. Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall

    * Complete cytogenetic response (CCyR) - 0% Ph+ metaphases * Partial cytogenetic response (PCyR) - \>0 to 35% Ph+ metaphases * Minor cytogenetic response (mCyR) - \>35 to 65% Ph+ metaphases * Minimal - \>65 to 95% Ph+ metaphases * None - \>95 to 100% Ph+ metaphases * Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

    Time frame: up to 66 cycles

  10. Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall

    Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - \>95 to 100% Ph+ metaphases

    Time frame: up to 66 cycles

  11. Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients

    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

    Time frame: From first dosing to the first CCyR up to 66 cycles

  12. Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients

    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

    Time frame: From first dosing to the first CCyR up to 66 cycles

  13. Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients

    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

    Time frame: From CCyR to loss of CCyR up to 66 cycles

  14. Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients

    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

    Time frame: 6, 12, 18, 24, 36, 48, 66 cycles

  15. Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients

    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

    Time frame: up to 66 cycles

  16. Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients

    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

    Time frame: up to 66 cycles

  17. Best Complete Hematological Response (CHR) by Time Point

    Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

    Time frame: cycle 3, 6, 9, 12, 18, 24, 36, 48, 66

  18. Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients

    Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

    Time frame: from first dosing to CHR, UP TO 66 CYCLES

  19. Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients

    Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

    Time frame: from first dosing to CHR, UP TO 66 CYCLES

  20. Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates

    Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.

    Time frame: From first dosing to the disease progression within 66 cycles

  21. Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients

    Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)

    Time frame: From first dosing to the disease progression or death up to 66 cycles

  22. Event Free Survival in Newly Diagnosed CML-CP Patients

    Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)

    Time frame: From first dosing to the disease progression or death up to 66 cycles

  23. Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates

    Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.

    Time frame: from first dosing to death up to 66 cycles

  24. Overall Survival (OS) in Newly Diagnosed CML-CP Patients

    Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.

    Time frame: from first dosing to death up to 66 cycles

  25. Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle

    BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.

    Time frame: By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles

  26. Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients

    PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.

    Time frame: Cycle 1 Day 8

  27. Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients

    PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.

    Time frame: Cycle 1 Day 8

  28. Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort

    To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.

    Time frame: from first dosing to 66 cycles

  29. Acceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation

    Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits. The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).

    Time frame: up to Cycle 12

  30. Mutational Assessment of BCR-ABL

    Emerging signs of resistance to nilotinib

    Time frame: up to 66 cycles

Other outcomes

  1. Long Term Effect of Nilotinib on Bone Metabolism

    The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.

    Time frame: Cycle 66

07

Results

Posted May 21, 2018

Participant flow

3 cohorts were planned based on disease classification. In 1 cohort no patients (pts) were enrolled so results presented are based on 2 cohorts. 34 imatinib/dasatinib resistant/intolerant CML-CP pts \& 25 newly diagnosed CML-CP pts were enrolled. 1 imatinib/dasatinib resistant/intolerant pt did not receive study drug \& was excluded from analysis.

Participant flow — Overall Study
MilestoneResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
Started3425
Treated3325
Untreated10
Completed1910
Not completed1515
Withdrew: Adverse event68
Withdrew: Withdrawal by subject23
Withdrew: Disease progression10
Withdrew: Administrative problems34
Withdrew: Protocol deviation20
Withdrew: Untreated10

Outcome measures

PrimaryRate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib

MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.

Time frame:
6 cycles
Reported as:
Number · Percentage of participants
Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib
Percentage of participantsResistant/Intolerant Ph+ CML in CP
Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib39.4 (22.9 to 57.9)
PrimaryMMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients

MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.

Time frame:
12 cycles
Reported as:
Number · Percentage of participants
MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients64.0 (42.5 to 82.0)
PrimaryRate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients

Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.

Time frame:
12 cycles
Reported as:
Number · Percentage of participants
Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients64.0 (42.5 to 82.0)
SecondaryMMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib

Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

Time frame:
By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days)
Reported as:
Number · Percentage of participants
MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib
Percentage of participantsResistant/Intolerant Ph+ CML in CP
By cycle 336.4 (20.4 to 54.9)
By cycle 645.5 (28.1 to 63.6)
By cycle 951.5 (33.5 to 69.2)
By cycle 1257.6 (39.2 to 74.5)
By cycle 1857.6 (39.2 to 74.5)
By cycle 2457.6 (39.2 to 74.5)
By cycle 3657.6 (39.2 to 74.5)
By cycle 4860.6 (42.1 to 77.1)
By cycle 6660.6 (42.1 to 77.1)
SecondaryMMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients

Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

Time frame:
by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days)
Reported as:
Number · Percentage of participants
MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
By cycle 312.0 (2.5 to 31.2)
By cycle 652.0 (31.3 to 72.2)
By cycle 956.0 (34.9 to 75.6)
By cycle 1264.0 (42.5 to 82.0)
By cycle 1868.0 (46.5 to 85.1)
By cycle 2468.0 (46.5 to 85.1)
By cycle 3676.0 (54.9 to 90.6)
By cycle 4876.0 (54.9 to 90.6)
By cycle 6676.0 (54.9 to 90.6)
SecondaryBest BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall

MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)

Time frame:
up to 66 cycles (1 cycle = 28 days)
Reported as:
Number · Percentage of participants
Best BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall
Percentage of participantsResistant/Intolerant Ph+ CML in CP
<=0.0032%12.1
> 0.0032% - ≤ 0.01%15.2
>0.01% - ≤ 0.1%33.3
>0.1% - ≤ 1%21.2
>1% - ≤ 10%9.1
> 10%6.1
Atypical transcripts at baseline3.0
SecondaryBest BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall

MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)

Time frame:
up to 66 cycles (1 cycle = 28 days)
Reported as:
Number · Percentage of participants
Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
≤ 0.0032%44.0
>0.0032% - ≤ 0.01%12.0
>0.01% - ≤ 0.1%20.0
>0.1% - ≤ 1%8.0
>1% - ≤ 10%8.0
>10%8.0
SecondaryTime to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR

Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.

Time frame:
From first dosing to the first MMR within 66 cycles period
Reported as:
Median · months
Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR
monthsResistant/Intolerant Ph+ CML in CP
Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR2.79 (0.03 to 5.75)
SecondaryTime to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR

Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.

Time frame:
From first dosing to the first MMR within 66 cycles period
Reported as:
Median · Months
Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR
MonthsNewly Diagnosed and Untreated Ph+ CML in First CP
Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR5.59 (5.52 to 10.84)
SecondaryDuration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR

Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.

Time frame:
from MMR until confirmed loss of MMR (Assessed up to 66 cycles)
Reported as:
Median · months
Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR
monthsResistant/Intolerant Ph+ CML in CP
Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMRNA (NA to NA)
SecondaryDuration of First MMR Among Newly Diagnosed Patients Who Achieved MMR

Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.

Time frame:
from MMR until confirmed loss of MMR (Assessed up to 66 cycles)es)
Reported as:
Median · months
Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMRNA (NA to NA)
SecondaryBest Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall

* Complete cytogenetic response (CCyR) - 0% Ph+ metaphases * Partial cytogenetic response (PCyR) - \>0 to 35% Ph+ metaphases * Minor cytogenetic response (mCyR) - \>35 to 65% Ph+ metaphases * Minimal - \>65 to 95% Ph+ metaphases * None - \>95 to 100% Ph+ metaphases * Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

Time frame:
up to 66 cycles
Reported as:
Number · Percentage of participants
Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall
Percentage of participantsResistant/Intolerant Ph+ CML in CP
Major cytogenetic response: Complete81.1
Major cytogenetic response: Partial3.0
Minimal3.0
None3.0
Missing9.1
SecondaryBest Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall

Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - \>95 to 100% Ph+ metaphases

Time frame:
up to 66 cycles
Reported as:
Number · Percentage of participants
Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall84.0 (63.9 to 95.5)
SecondarySummary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients

Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

Time frame:
From first dosing to the first CCyR up to 66 cycles
Reported as:
Median · months
Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients5.55 (5.49 to 5.59)
SecondaryKaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients

Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

Time frame:
From first dosing to the first CCyR up to 66 cycles
Reported as:
Median · months
Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients5.6 (5.5 to 5.6)
SecondaryKaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients

Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.

Time frame:
From CCyR to loss of CCyR up to 66 cycles
Reported as:
Median · months
Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP PatientsNA (NA to NA)
SecondaryBest Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients

Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

Time frame:
6, 12, 18, 24, 36, 48, 66 cycles
Reported as:
Number · Percentage of participants
Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
by cycle 688.0 (68.8 to 97.5)
by cycle 1288.0 (68.8 to 97.5)
by cycle 1888.0 (68.8 to 97.5)
by cycle 2488.0 (68.8 to 97.5)
by cycle 3688.0 (68.8 to 97.5)
by cycle 4888.0 (68.8 to 97.5)
by cycle 6688.0 (68.8 to 97.5)
SecondarySummary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients

Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

Time frame:
up to 66 cycles
Reported as:
Median · months
Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients5.55 (5.52 to 5.59)
SecondaryKaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients

Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.

Time frame:
up to 66 cycles
Reported as:
Median · months
Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients5.55 (5.52 to 5.59)
SecondaryBest Complete Hematological Response (CHR) by Time Point

Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

Time frame:
cycle 3, 6, 9, 12, 18, 24, 36, 48, 66
Reported as:
Number · Percentage of participants
Best Complete Hematological Response (CHR) by Time Point
Percentage of participantsNewly Diagnosed and Untreated Ph+ CML in First CP
by cycle 376.0 (54.9 to 90.6)
by cycle 684.0 (63.9 to 95.5)
by cycle 988.0 (68.8 to 97.5)
by cycle 1292.0 (74.0 to 99.0)
by cycle 1892.0 (74.0 to 99.0)
by cycle 2492.0 (74.0 to 99.0)
by cycle 3692.0 (74.0 to 99.0)
by cycle 4892.0 (74.0 to 99.0)
by cycle 6692.0 (74.0 to 99.0)
SecondarySummary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients

Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

Time frame:
from first dosing to CHR, UP TO 66 CYCLES
Reported as:
Median · months
Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients0.95 (0.72 to 2.76)
SecondaryKaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients

Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP

Time frame:
from first dosing to CHR, UP TO 66 CYCLES
Reported as:
Median · months
Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients1.0 (1.0 to 2.8)
SecondaryTime to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates

Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.

Time frame:
From first dosing to the disease progression within 66 cycles
Reported as:
Median · months
Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates
monthsResistant/Intolerant Ph+ CML in CP
Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier EstimatesNA (NA to NA)
SecondaryEvent Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients

Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)

Time frame:
From first dosing to the disease progression or death up to 66 cycles
Reported as:
Median · months
Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients
monthsResistant/Intolerant Ph+ CML in CP
Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP PatientsNA (NA to NA)
SecondaryEvent Free Survival in Newly Diagnosed CML-CP Patients

Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)

Time frame:
From first dosing to the disease progression or death up to 66 cycles
Reported as:
Median · months
Event Free Survival in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Event Free Survival in Newly Diagnosed CML-CP PatientsNA (NA to NA)
SecondaryOverall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates

Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.

Time frame:
from first dosing to death up to 66 cycles
Reported as:
Median · months
Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates
monthsResistant/Intolerant Ph+ CML in CP
Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier EstimatesNA (NA to NA)
SecondaryOverall Survival (OS) in Newly Diagnosed CML-CP Patients

Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.

Time frame:
from first dosing to death up to 66 cycles
Reported as:
Median · months
Overall Survival (OS) in Newly Diagnosed CML-CP Patients
monthsNewly Diagnosed and Untreated Ph+ CML in First CP
Overall Survival (OS) in Newly Diagnosed CML-CP PatientsNA (NA to NA)
SecondaryPharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle

BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.

Time frame:
By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles
Reported as:
Number · Percentage of participants
Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle
Percentage of participantsResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
By Cycle 336.4 (20.4 to 54.9)12.0 (2.5 to 31.2)
By Cycle 645.5 (28.1 to 63.6)52.0 (31.3 to 72.2)
By Cycle 951.5 (33.5 to 69.2)56.0 (34.9 to 75.6)
By Cycle 1257.6 (39.2 to 74.5)64.0 (42.5 to 82.0)
By Cycle 1857.6 (39.2 to 74.5)68.0 (46.5 to 85.1)
By Cycle 2457.6 (39.2 to 74.5)68.0 (46.5 to 85.1)
By Cycle 3657.6 (39.2 to 74.5)76.0 (54.9 to 90.6)
By Cycle 4860.6 (42.1 to 77.1)76.0 (54.9 to 90.6)
By Cycle 6660.6 (42.1 to 77.1)76.0 (54.9 to 90.6)
SecondaryPharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients

PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.

Time frame:
Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients
ng/mLResistant/Intolerant Ph+ CML in CP
Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients1407.89 ± 41.67
SecondaryPharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients

PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.

Time frame:
Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients
ng/mLNewly Diagnosed and Untreated Ph+ CML in First CP
Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients1274.30 ± 46.21
SecondaryGrowth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort

To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.

Time frame:
from first dosing to 66 cycles
Reported as:
Number · Percentage of participants
Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort
Percentage of participantsResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
Decrease from baseline of 1 SDS category (n=32,24)27.332.0
Decrease from baseline of 2 SDS categories (n=32, 24)3.016.0
Decrease from baseline of 3 SDS categories(n= 32, 24)6.14.0
SecondaryAcceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation

Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits. The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).

Time frame:
up to Cycle 12
Reported as:
Number · Percentage of participants
Acceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation
Percentage of participantsAll Patients
Cycle (C) 1 Day (D) 1: Completed questionnaire - Patients75.9
C1D1: Completed questionnaire - Parents/Caregivers22.4
C1D1: Patients who swallowed capsule whole91.4
C1D1: Patients had capsule mixed with apple sauce6.9
C1D1: Patients who reported no taste/unable to answer question43.1
C1D1: Patients who reported taste as good/very good12.1
C1D1: Patients who reported taste as not good/not bad34.5
C1D1: Reported capsule to be very easy/easy to administer79.3
C1D28: Completed questionnaire - Patients55.2
C1D28: Completed questionnaire - Parents/Caregivers22.4
C12D28: Completed questionnaire - Patients55.2
C12D28: Completed questionnaire - Parents/Caregivers22.4
SecondaryMutational Assessment of BCR-ABL

Emerging signs of resistance to nilotinib

Time frame:
up to 66 cycles
Reported as:
Number · Percentage of participants
Mutational Assessment of BCR-ABL
Percentage of participantsResistant/i Ntolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
Patients with >=1 evaluable post-baseline mutational analysis39.432.0
Patients with any emergent mutation on treatment0.00.0
Patients with multiple emergent mutations on treatment0.00.0
Other pre-specifiedLong Term Effect of Nilotinib on Bone Metabolism

The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.

Time frame:
Cycle 66
Reported as:
Mean · Percentage of participants
Long Term Effect of Nilotinib on Bone Metabolism
Percentage of participantsResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
X-ray (n= 6, 0)-0.61 ± 1.703—
DEXA (n = 14, 10)-0.35 ± 1.243-0.70 ± 1.043
Post-hocAll Collected Deaths

On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 64.5 months (treatment duration ranged from 0.7 to 63.5 months). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 7 years.

Time frame:
approx. 64.5 months, approx. 7 years
Reported as:
Number · Participants
All Collected Deaths
ParticipantsResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CP
On-treatment deaths00
Total Deaths13

Adverse events

Collected over On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 64.5 months (treatment duration ranged from 0.7 to 63.5 months). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Resistant/Intolerant Ph+ CML in CP0/33 (0%)11/33 (33.3%)33/33 (100%)
Newly Diagnosed and Untreated Ph+ CML in First CP0/25 (0%)4/25 (16%)25/25 (100%)
All Patients0/58 (0%)15/58 (25.9%)58/58 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CPAll Patients
PyrexiaGeneral disorders2/330/252/58
Abdominal painGastrointestinal disorders0/331/251/58
DiarrhoeaGastrointestinal disorders0/331/251/58
HyperbilirubinaemiaHepatobiliary disorders0/331/251/58
Gastroenteritis viralInfections and infestations1/331/252/58
Viral infectionInfections and infestations1/331/252/58
Electrocardiogram QT prolongedInvestigations0/331/251/58
Weight decreasedInvestigations0/331/251/58
Facial paralysisNervous system disorders0/331/251/58
HeadacheNervous system disorders0/331/251/58
Most frequent other events
Showing 10 of 94
Most frequent other events
EventResistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CPAll Patients
HeadacheNervous system disorders13/3314/2527/58
Alanine aminotransferase increasedInvestigations10/3311/2521/58
RashSkin and subcutaneous tissue disorders7/3311/2518/58
NauseaGastrointestinal disorders8/3310/2518/58
Blood bilirubin increasedInvestigations12/3310/2522/58
PyrexiaGeneral disorders11/339/2520/58
Aspartate aminotransferase increasedInvestigations8/339/2517/58
VomitingGastrointestinal disorders7/338/2515/58
HyperbilirubinaemiaHepatobiliary disorders4/338/2512/58
Upper respiratory tract infectionInfections and infestations10/337/2517/58

Baseline characteristics

Full Analysis Set (FAS): All patients who received at least one dose of study medication.

Age, Customized
Age, Customized(Participants)Resistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CPTotal
1 to < 12 years12618
12 to < 18 years211940
Sex: Female, Male
Sex: Female, Male(Participants)Resistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CPTotal
Female121224
Male211334
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Resistant/Intolerant Ph+ CML in CPNewly Diagnosed and Untreated Ph+ CML in First CPTotal
Caucasian121830
Black303
Asian16723
Native American101
Other101
08

Study locations

36 sites
  • Loma Linda University Cancer Center
    Loma Linda, California 92350, United States
  • Lucile Salter Packard Children's Hospital at Stanford
    Palo Alto, California 94304, United States
  • Nemours Childrens Hospital
    Orlando, Florida 32827, United States
  • St. Mary's Hospital
    West Palm Beach, Florida 33407, United States
  • Johns Hopkins Oncology Center ORA
    Baltimore, Maryland 21231, United States
  • UNC Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Nationwide Childrens Hospital
    Columbus, Ohio 43205, United States
  • University of Texas Southwestern Medical Center Oncology
    Dallas, Texas 75235, United States
  • Cook Children's Medical Center Oncology
    Fort Worth, Texas 76104, United States
  • Seattle Childrens Hospital
    Seattle, Washington 98105, United States
  • Novartis Investigative Site
    Bordeaux, Aquitaine 33076, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Paris Cedex, 75019, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Budapest, 1094, Hungary
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Monza, MB 20900, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Yokohama-city, Kanagawa 232-8555, Japan
  • Novartis Investigative Site
    Sakyo Ku, Kyoto 606 8507, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160 8582, Japan
  • Novartis Investigative Site
    Saitama, 330 8777, Japan
  • Novartis Investigative Site
    Shizuoka, 420 8660, Japan
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Kuala Lumpur, 50589, Malaysia
  • Novartis Investigative Site
    Rotterdam, 3015 CE, Netherlands
  • Novartis Investigative Site
    Moscow, 117198, Russian Federation
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Muang, Chiangmai 50200, Thailand
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Bristol, BS2 8BJ, United Kingdom
09

References and documents

Publications

  • Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv. 2021 Jul 27;5(14):2925-2934. doi: 10.1182/bloodadvances.2020003759. PubMed 34309636 ↗
  • Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. doi: 10.1182/blood.2019000069. PubMed 31511239 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Jun 2016, 33 months.

Results were first posted in May 2018, 1 year 11 months after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 33 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2013
First posted
May 1, 2013
StartActual
Aug 20, 2013
Primary completionActual
Jun 1, 2016
CompletionActual
Aug 28, 2020
Results first posted
May 21, 2018
Last update
Apr 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01844765
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Aug 20, 2013
Primary completion
Jun 1, 2016
Completion
Aug 28, 2020
Results posted
May 21, 2018
Last update
Apr 22, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion